Medicare AdvantageAdministrativeLow impact
MA07.044b, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·NJ · Pulmonology, Internal Medicine, Family Medicine +1 more·Medical Policy
We identified it
Jun 19, 2026
Summary
This is a reissue with no substantive changes to Independence Blue Cross Medicare Advantage policy MA07.044b. The policy maintains coverage for exhaled nitric oxide (eNO/FeNO) testing for asthma diagnosis and management (limited to 5 tests per 12 months), while continuing to classify exhaled breath condensate testing and eNO testing for other respiratory disorders as experimental/investigational and not covered.
Action Required
No immediate action required. This is a routine annual policy reissue with no changes to coverage criteria, billing codes, or medical necessity definitions. Billing team should verify current policy file is MA07.044b dated 06/24/2026 for New Jersey Medicare Advantage claims involving exhaled nitric oxide or breath condensate testing. Continue applying existing coverage rules: cover eNO for asthma diagnosis and management (max 5 tests/year per CPT 95012); deny all exhaled breath condensate tests (CPT 83987) and eNO testing for COPD/chronic cough as experimental.